ANP (Atrial Natriuretic Peptide) vs Hexarelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →Hexarelin
Hexarelin is a potent synthetic hexapeptide growth hormone secretagogue. It provides the strongest GH release among GHRPs but is associated with rapid desensitization of receptors.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | Hexarelin |
|---|---|---|
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | Acts as a ghrelin mimetic with high potency at the GHS receptor. Provides powerful GH release but receptor desensitization occurs faster than with other GHRPs, requiring cycling. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Typical dosing: 100-200mcg administered 2-3 times daily for 4-6 weeks, followed by an equal off period to allow receptor resensitization. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Subcutaneous injection. Cycling is essential to maintain effectiveness. Often used in short bursts rather than continuous protocols. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Water retention, cortisol and prolactin increase, hunger (moderate), tingling, and potential blood pressure effects. |
| Best For |
What They Have in Common
Both ANP (Atrial Natriuretic Peptide) and Hexarelin are commonly used for: